Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers

头孢吡肟 生物等效性 哌拉西林/他唑巴坦 他唑巴坦 哌拉西林 利奈唑啉 医学 药理学 最大值 药代动力学 抗生素 化学 亚胺培南 万古霉素 抗生素耐药性 细菌 生物 铜绿假单胞菌 生物化学 遗传学 金黄色葡萄球菌
作者
Felix Bergmann,Beatrix Wulkersdorfer,Zoe Oesterreicher,Martin Bauer,Valentin al Jalali,Alina Nussbaumer‐Pröll,Michael Wölfl‐Duchek,Anselm Jorda,Edith Lackner,Birgit Reiter,Thomas Stimpfl,Nicolás Ballarini,Franz König,Markus Zeitlinger
出处
期刊:Journal of Antimicrobial Chemotherapy [Oxford University Press]
卷期号:77 (11): 3086-3092 被引量:2
标识
DOI:10.1093/jac/dkac285
摘要

The efficacy and quality of generic antibacterial drug formulations are often questioned by both healthcare specialists and patients. Therefore, the present study investigated the interchangeability of generic drugs with their originators by comparing bioequivalence parameters and stability data of generic cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs.In this open-label, randomized, crossover bioequivalence study, three groups of 12 healthy volunteers each received a single intravenous infusion of either 2 g of cefepime or 4.5 g of piperacillin/tazobactam and two generic formulations, or 600 mg of linezolid and one generic formulation. Plasma sampling was performed, with a 5 day washout period between study days. Stability was tested by storing reconstituted generic and originator products according to their own storage specifications and those of the comparator products. All concentrations were measured by LC-MS.Similar ratios of generic/originator (90% CI) Cmax were observed for Cefepime-MIP/Maxipime [93.7 (88.4-99.4)], Cefepime Sandoz/Maxipime [95.9 (89.1-103.2)], Linezolid Kabi/Zyvoxid [104.5 (91.1-119.9)], Piperacillin Kabi/Tazobac [95.9 (90.4-101.7)], Piperacillin Aurobindo/Tazobac [99.7 (84.9-104.7)], Tazobactam Kabi/Tazobac [93.4 (87.4-99.8)] and Tazobactam Aurobindo/Tazobac [97.4 (89.7-105.8)]. Accordingly, similar ratios of AUC0-t were observed for Cefepime-MIP/Maxipime [91.1 (87.6-94.8)], Cefepime Sandoz/Maxipime [97.9 (92.5-103.5)], Linezolid Kabi/Zyvoxid [99.7 (93.3-106.6)], Piperacillin Kabi/Tazobac [92.2 (88.3-96.3)], Piperacillin Aurobindo/Tazobac [99.9 (97.0-102.8)], Tazobactam Kabi/Tazobac [91.4 (86.4-96.7)] and Tazobactam Aurobindo/Tazobac [98.8 (94.3-103.6)]. Stable and similar concentrations were measured for all contiguous substances, regardless of storage conditions.Compared with their respective originator drugs, generic cefepime, linezolid and piperacillin/tazobactam met the predetermined bioequivalence criteria. All formulations were stable under the storage conditions of their respective comparators.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
拾光完成签到,获得积分10
1秒前
Nancy0818完成签到 ,获得积分10
2秒前
3秒前
共享精神应助633采纳,获得10
3秒前
冷艳怜烟发布了新的文献求助10
4秒前
5秒前
CMUSK发布了新的文献求助10
5秒前
6秒前
mumu发布了新的文献求助10
6秒前
wwawi发布了新的文献求助10
7秒前
顾矜应助王玉婷采纳,获得10
7秒前
欢乐谷完成签到,获得积分10
10秒前
11秒前
Giaogiao发布了新的文献求助50
11秒前
汉堡包应助幻之樱花33采纳,获得10
11秒前
11秒前
13秒前
13秒前
奔跑917完成签到,获得积分10
14秒前
16秒前
16秒前
Jessie Li发布了新的文献求助10
16秒前
17秒前
NexusExplorer应助syx采纳,获得10
17秒前
LIU完成签到,获得积分10
17秒前
鸢北发布了新的文献求助10
18秒前
哭泣的翠丝完成签到,获得积分10
19秒前
阔达水之发布了新的文献求助10
19秒前
20秒前
tackhwa发布了新的文献求助10
20秒前
Yuan完成签到,获得积分10
20秒前
让让完成签到,获得积分10
20秒前
冷艳怜烟完成签到,获得积分10
20秒前
JunHan完成签到,获得积分10
21秒前
科研通AI6.1应助yun采纳,获得30
23秒前
让让发布了新的文献求助10
23秒前
24秒前
缥缈的忆梅关注了科研通微信公众号
24秒前
26秒前
wtc完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Kinesiophobia : a new view of chronic pain behavior 3000
Les Mantodea de guyane 2500
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 2000
Signals, Systems, and Signal Processing 510
Discrete-Time Signals and Systems 510
Brittle Fracture in Welded Ships 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5945097
求助须知:如何正确求助?哪些是违规求助? 7097126
关于积分的说明 15898393
捐赠科研通 5077084
什么是DOI,文献DOI怎么找? 2730270
邀请新用户注册赠送积分活动 1690179
关于科研通互助平台的介绍 1614549